Coherus Oncology (CHRS) Shares Outstanding (2013 - 2026)

Coherus Oncology has reported Shares Outstanding (Entity) for 14 years, with the latest figure at $154.2 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 33.05% year-over-year to $154.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.2 million (up 33.05% YoY) and the FY2025 annual result came in at $121.2 million, up 4.79% from the prior year.
• Shares Outstanding (Entity) grew to $154.2 million in Q1 2026 per CHRS's latest filing, from $121.2 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $154.2 million in Q1 2026 and troughed at $77.3 million in Q1 2022.
• A 5-year average of $105.4 million and a median of $113.5 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) surged 42.31% in 2023, then gained 0.89% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $78.9 million in 2022, then surged by 42.31% to $112.2 million in 2023, then grew by 3.03% to $115.6 million in 2024, then increased by 4.79% to $121.2 million in 2025, then gained by 27.29% to $154.2 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $154.2 million, $121.2 million, and $116.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.